
SPRB Stock Forecast & Price Target
SPRB Analyst Ratings
Bulls say
Spruce Biosciences is supported by a compelling regulatory and clinical setup for TA-ERT, with FDA commentary reinforcing flexibility in rare diseases and a clear path toward its expected 4Q26 BLA submission. The company’s lead program addresses a severe unmet need in MPS IIIB, and its evidence package combines biomarker reduction in CSF heparan sulfate with longer-term neurodevelopmental and imaging data, while competitors remain several years behind and mostly early-stage. Financially, the stock appears mispriced versus the ~$60M EV and ~$130M market cap, especially with $96M in cash providing runway into 2H27, a ~$150M+ PRV opportunity, and modeled peak sales above $300M.
Bears say
Spruce Biosciences is a development-stage biotech with a very limited pipeline, leaving valuation heavily dependent on TA-ERT for MPS IIIB while SPR202 remains only in preclinical development. Its negative outlook is driven by major clinical and regulatory uncertainty, since no approved MPS IIIB therapies exist and approval may hinge on Phase 2 surrogate biomarker data rather than definitive outcomes, while weekly intracerebroventricular dosing could also constrain adoption. Financially, the company reported 2Q26 OpEx of $17M, a net loss of $16M, and a per-share loss of ($6.68), and it is expected to keep burning cash and likely raise additional capital, creating dilution risk for shareholders.
This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Spruce Biosciences Inc (SPRB) Forecast
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares